Citalopram (Celexa) for Excoriation (Skin-Picking) Disorder
There is no established recommended dose of citalopram specifically for skin-picking disorder, as no medication is FDA-approved for this condition and the evidence for SSRIs in excoriation disorder is limited and inconsistent. 1, 2
Evidence Base for SSRIs in Skin-Picking Disorder
The evidence supporting SSRI use for excoriation disorder is weak:
- SSRIs have shown variable success in treating skin-picking disorder, with no specific dosing guidelines established for this indication 1
- One open-label trial of escitalopram (a closely related SSRI) used doses up to 25 mg daily (mean maximally tolerated dose) and found approximately 50% of completers met full response criteria, though this was an uncontrolled study 3
- SSRIs should be considered primarily in cases with significant psychiatric comorbidities or when first-line treatments have failed 2
Extrapolation from Related Conditions
If citalopram is being considered off-label for skin-picking disorder, dosing guidance can be extrapolated from other body-focused repetitive behaviors and anxiety-related conditions:
- Citalopram 20-40 mg daily has been used for premature ejaculation (another compulsive behavior disorder) in guidelines, suggesting this range may be reasonable for excoriation disorder 4
- Standard antidepressant dosing typically starts at 20 mg daily with potential titration to 40 mg based on response 4
Important Caveats and Warnings
Critical safety considerations:
- Citalopram has a maximum FDA-recommended dose of 40 mg daily due to QT prolongation risk, with lower maximum doses (20 mg) recommended for patients over 60 years, those with hepatic impairment, or CYP2C19 poor metabolizers 5
- Monitor for serotonin syndrome, particularly if combining with other serotonergic agents 4
- Avoid abrupt discontinuation due to SSRI withdrawal syndrome risk; taper gradually over 10-14 days 5
- Screen for bipolar disorder history, as SSRIs can precipitate mania 4
- Monitor for suicidal ideation, particularly in younger patients 4
Recommended Treatment Algorithm
First-line approach:
- Start with N-acetylcysteine (NAC) 1200-3000 mg/day, which has the strongest evidence (randomized controlled trial showing 47% response rate vs 19% placebo) and favorable side effect profile 6, 2
- Combine with habit reversal therapy (HRT) or stimulus control behavioral interventions 2
Second-line considerations:
- If NAC and behavioral therapy fail after 12 weeks, consider citalopram 20 mg daily, titrating to 40 mg if needed after 4-6 weeks based on tolerability and response 4, 2
- Allow at least 6-12 weeks at therapeutic dose before determining efficacy, as with other SSRI indications 5
Treatment-resistant cases:
- Consider augmentation strategies (e.g., aripiprazole added to an SNRI like venlafaxine has case report support) or switching to alternative agents 7
Monitoring Parameters
- Assess skin-picking severity at baseline and every 2-4 weeks using standardized measures
- Monitor for adverse effects within 24-48 hours of dose initiation or increases 5
- ECG monitoring may be warranted in patients with cardiac risk factors given QT prolongation concerns 5
- Evaluate for emergence of suicidal ideation, particularly in the first weeks of treatment 4